Intarcia Therapeutics
From Wikipedia, the free encyclopedia
Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware.[1][2] It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004.[1] In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, North Carolina, where it discovers and develops peptides for its drug delivery system.[3]
Company type | Private |
---|---|
Industry | pharmaceutical industry |
Founded | Hayward, California, United States (1995 (1995)) |
Headquarters | , United States |
Key people |
|
Products | Medici Drug Delivery System |
Website | intarcia |
In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively.[4] By 2012, Kurt Graves had replaced Karling Leung as President and CEO.[5] Kurt Graves has been with Intarcia since August 2010, first serving as Executive Chairman before becoming President and CEO in April 2012.[6]
As of 2016[update], Intarcia is engaged in development of a "potential once-a-year type 2 diabetes treatment". Referred to as ITCA 650, the therapeutic consists of exenatide delivered via its Medici Drug Delivery System,[7] "a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides".[1] The drug was rejected for FDA approval in 2017 and 2020.[8]